Reagila

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
07-06-2022
Toote omadused Toote omadused (SPC)
07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
18-09-2017

Toimeaine:

cariprazine hydrochloride

Saadav alates:

Gedeon Richter

ATC kood:

N05AX15

INN (Rahvusvaheline Nimetus):

cariprazine

Terapeutiline rühm:

Psycholeptics

Terapeutiline ala:

Schizophrenia

Näidustused:

Reagila is indicated for the treatment of schizophrenia in adult patients.

Toote kokkuvõte:

Revision: 7

Volitamisolek:

Authorised

Loa andmise kuupäev:

2017-07-13

Infovoldik

                                40
B. PACKAGE LEAFLET
41
PACKAGE LEAFLET: INFORMATION FOR THE USER
REAGILA 1.5 MG HARD CAPSULES
REAGILA 3 MG HARD CAPSULES
REAGILA 4.5 MG HARD CAPSULES
REAGILA 6 MG HARD CAPSULES
cariprazine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Reagila is and what it is used for
2.
What you need to know before you take Reagila
3.
How to take Reagila
4.
Possible side effects
5.
How to store Reagila
6.
Contents of the pack and other information
1.
WHAT REAGILA IS AND WHAT IT IS USED FOR
Reagila contains the active substance cariprazine and belongs to a
group of medicines called
antipsychotics. It is used to treat adults with schizophrenia.
Schizophrenia is a disease characterised by symptoms such as hearing,
seeing or sensing things which
are not there (hallucination), suspiciousness, mistaken beliefs,
incoherent speech and behaviour and
emotional flatness. People with this condition may also feel
depressed, guilty, anxious, tense, or not
being able to start or keep up planned activities, unwillingness to
speak, lack of emotional response to
a situation that would normally stimulate feelings in others.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE REAGILA
DO NOT TAKE REAGILA
-
if you are allergic to cariprazine or any of the other ingredients of
this medicine (listed in
section 6).
-
if you are taking medicines used to treat:
-
hepatitis caused by the hepatitis C virus (medicines containing
boceprevir and telaprevir)
-
bacterial infections (medicines containing clarithromycin,
telithromycin, erythromycin
and nafcillin)
-

                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Reagila 1.5 mg hard capsules
Reagila 3 mg hard capsules
Reagila 4.5 mg hard capsules
Reagila 6 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Reagila 1.5 mg hard capsules
Each hard capsule contains cariprazine hydrochloride corresponding to
1.5 mg cariprazine.
Reagila 3 mg hard capsules
Each hard capsule contains cariprazine hydrochloride corresponding to
3 mg cariprazine.
Excipient with known effect
Each hard capsule contains 0.0003 mg Allura red AC (E 129).
Reagila 4.5 mg hard capsules
Each hard capsule contains cariprazine hydrochloride corresponding to
4.5 mg cariprazine.
Excipient with known effect
Each hard capsule contains 0.0008 mg Allura red AC (E 129).
Reagila 6 mg hard capsules
Each hard capsule contains cariprazine hydrochloride corresponding to
6 mg cariprazine.
Excipient with known effect
Each hard capsule contains 0.0096 mg Allura red AC (E 129).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule
Reagila 1.5 mg hard capsules
‘Size 4’ (approximately 14.3 mm in length) hard gelatin capsule
with white opaque cap and white
opaque body imprinted with “GR 1.5” on the capsule body with black
ink. The capsules are filled with
white to yellowish white powder mixture.
Reagila 3 mg hard capsules
‘Size 4’ (approximately 14.3 mm in length) hard gelatin capsule
with green opaque cap and white
opaque body imprinted with “GR 3” on the capsule body with black
ink. The capsules are filled with
white to yellowish white powder mixture.
3
Reagila 4.5 mg hard capsules
‘Size 4’ (approximately 14.3 mm in length) hard gelatin capsule
with green opaque cap and green
opaque body imprinted with “GR 4.5” on the capsule body with white
ink. The capsules are filled with
white to yellowish white powder mixture.
Reagila 6 mg hard capsules
‘Size 3’ (approximately 15.9 mm in length) hard gelatin capsule
with purple opaque cap and white
opaque body imprinted with “GR 6” on th
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 07-06-2022
Toote omadused Toote omadused bulgaaria 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 18-09-2017
Infovoldik Infovoldik hispaania 07-06-2022
Toote omadused Toote omadused hispaania 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 18-09-2017
Infovoldik Infovoldik tšehhi 07-06-2022
Toote omadused Toote omadused tšehhi 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 18-09-2017
Infovoldik Infovoldik taani 07-06-2022
Toote omadused Toote omadused taani 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande taani 18-09-2017
Infovoldik Infovoldik saksa 07-06-2022
Toote omadused Toote omadused saksa 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande saksa 18-09-2017
Infovoldik Infovoldik eesti 07-06-2022
Toote omadused Toote omadused eesti 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande eesti 18-09-2017
Infovoldik Infovoldik kreeka 07-06-2022
Toote omadused Toote omadused kreeka 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 18-09-2017
Infovoldik Infovoldik prantsuse 07-06-2022
Toote omadused Toote omadused prantsuse 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 18-09-2017
Infovoldik Infovoldik itaalia 07-06-2022
Toote omadused Toote omadused itaalia 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 18-09-2017
Infovoldik Infovoldik läti 07-06-2022
Toote omadused Toote omadused läti 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande läti 18-09-2017
Infovoldik Infovoldik leedu 07-06-2022
Toote omadused Toote omadused leedu 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande leedu 18-09-2017
Infovoldik Infovoldik ungari 07-06-2022
Toote omadused Toote omadused ungari 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande ungari 18-09-2017
Infovoldik Infovoldik malta 07-06-2022
Toote omadused Toote omadused malta 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande malta 18-09-2017
Infovoldik Infovoldik hollandi 07-06-2022
Toote omadused Toote omadused hollandi 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 18-09-2017
Infovoldik Infovoldik poola 07-06-2022
Toote omadused Toote omadused poola 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande poola 18-09-2017
Infovoldik Infovoldik portugali 07-06-2022
Toote omadused Toote omadused portugali 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande portugali 18-09-2017
Infovoldik Infovoldik rumeenia 07-06-2022
Toote omadused Toote omadused rumeenia 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 18-09-2017
Infovoldik Infovoldik slovaki 07-06-2022
Toote omadused Toote omadused slovaki 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 18-09-2017
Infovoldik Infovoldik sloveeni 07-06-2022
Toote omadused Toote omadused sloveeni 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 18-09-2017
Infovoldik Infovoldik soome 07-06-2022
Toote omadused Toote omadused soome 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande soome 18-09-2017
Infovoldik Infovoldik rootsi 07-06-2022
Toote omadused Toote omadused rootsi 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 18-09-2017
Infovoldik Infovoldik norra 07-06-2022
Toote omadused Toote omadused norra 07-06-2022
Infovoldik Infovoldik islandi 07-06-2022
Toote omadused Toote omadused islandi 07-06-2022
Infovoldik Infovoldik horvaadi 07-06-2022
Toote omadused Toote omadused horvaadi 07-06-2022
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 18-09-2017

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu